You are interested to join the Center for Infection and Immunity of Lille to develop an innovative project? The European Metropolis of Lille can support you with up to 150 000€ for a period of 3 years.
Application deadline: 26/05/2021
FOCUS ON ...
Antibiotic (multi)drug resistance is a large and growing global health problem, particularly for tuberculosis and numerous nosocomial bacterial infections. In support of this, the World Health Organisation has proclaimed that research and drug development to combat these drug resistant bacteria is of critical priority. The CBA team investigates a series of novel strategies aimed to combat antibiotic resistant bacteria with current research focussing on the discovery and development of novel antibiotics and the development of innovate strategies that improve antibiotic penetration into bacteria.
RECENT SELECTED PUBLICATIONS
Persistence and dynamics of fluorescent Lactobacillus plantarum in the healthy versus inflamed gut
Salomé-Desnoulez S, Poiret S, Foligné B, Muharram G, Peucelle V, Lafont F & Daniel C
Gut microbes (2021)
SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota.
Harry Sokol, Vanessa Contreras, Pauline Maisonnasse, Aurore Desmons, Benoit Delache, Valentin Sencio, Arnaud Machelart, Angela Brisebarre, Lydie Humbert, Lucie Deryuter, Emilie Gauliard, Severine Heumel, Dominique Rainteau, Nathalie Dereuddre-Bosquet, Elisabeth Menu, Raphael Ho Tsong Fang, Antonin Lamaziere, Loic Brot, Celine Wahl, Cyriane Oeuvray, Nathalie Rolhion, Sylvie Van Der Werf, Stéphanie Ferreira, Roger Le Grand & François Trottein
The UPR sensor IRE1α promotes dendritic cell responses to control Toxoplasmagondii infection
Anaïs F Poncet, Victor Bosteels, Eik Hoffmann, Sylia Chehade, Sofie Rennen, Ludovic Huot, Véronique Peucelle, Sandra Maréchal, Jamal Khalife, Nicolas Blanchard, Sophie Janssens, Sabrina Marion.
EMBO Rep (2021)
TgAP2IX-5 is a key transcriptional regulator of the asexual cell cycle division in Toxoplasma gondii.
Asma S. Khelifa, Cecilia Guillen Sanchez, Kevin M. Lesage, Ludovic Huot, Thomas Mouveaux, Pierre Pericard, Nicolas Barois, Helene Touzet, Guillemette Marot, Emmanuel Roger et Mathieu Gissot.
Nat Commun (2021)
Plasmodium yoelii Uses a TLR3-Dependent Pathway to Achieve Mammalian Host Parasitism
Keswani T, Delcroix-Genete D, Herbert F, Leleu I, Lambert C, Draheim M, Salome-Desnoulez S, Saliou JM, Cazenave PA, Silvie O, Roland J, Pied S. (2020)
Our Youtube chanel
Third episode in the series dedicated to researching Covid-19. This webinar is moderated by Marie Treibert, science popularizer on the La Boîte à curiosités channel. She questions Sandrine Belouzard, virologist and CNRS researcher, who answers all questions relating to antivirals in the treatment of Covid-19. What is the difference between a vaccine and an antiviral treatment? How does an antiviral work? Who will benefit from it? Do we favor therapeutic repositioning or research for a new drug? Through definitions, a press review and an interview, this webinar takes stock of the subject.
One year after the first cases of COVID-19, researchers of the Center for Infection & Immunity of Lille present the current knowledge on SARS-CoV-2 in the context of a series of conferences organized by the Lille Research Taskforce on COVID-19, in partnership with the Society of Sciences, Agriculture and Arts of Lille.
Researchs against Covid-19 at the Institut Pasteur in Lille.
Coronaviruses, specificities and prospects for treatment by Jean Dubuisson, director of the Center for Infection & Immunity of Lille
More than 60 diseases can be transmitted to humans by rats. Among them, Plague, believed to be a disease of the past, has never been eradicated ...
"While bats are not to blame for everything, they have played a role in the transmission of at least 11 viruses" ...
COVID-19: Jean Dubuisson tells us about ANTI-CoV, a project supported by the FRM